Journals / Eurasian Journal of Pulmonology / 2019 / Cilt: 21 - Sayı: 3

Does neutrophil-to-lymphocyte ratio have a role among the other prognostic factors of nonsmall cell lung cancer?

Pages
187–192
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

These parameters were tested for its association with the 1‑year, 2‑year, and overallsurvival (OS); OS was calculated by the Kaplan–Meier analysis.RESULTS: A total of 121 patients with a median age of 61.9 (range 34–84), 14 (11.6%) female, and107 (88.4%) males were included in the study.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:INTRODUCTION: Neutrophil‑to‑lymphocyte ratio (NLR), an index of systemic inflammation, has beenassociated with poor survival for many cancers.
📊
Key Findings & Data:The aim of this study was to investigate the clinicalsignificance of blood NLR in nonsmall cell lung cancer (NSCLC) as a prognostic factor.METHODS: We retrospectively reviewed medical records of patients with NSCLC and collected datafrom December 2009 to September 2013.
💡
Conclusion & Impact:These parameters were tested for its association with the 1‑year, 2‑year, and overallsurvival (OS); OS was calculated by the Kaplan–Meier analysis.RESULTS: A total of 121 patients with a median age of 61.9 (range 34–84), 14 (11.6%) female, and107 (88.4%) males were included in the study.
🔬Design:Review & Systematic Survey
📍Scope:2009 Verileri
⚙️Variables:Domain Parameters

Abstract

INTRODUCTION: Neutrophil‑to‑lymphocyte ratio (NLR), an index of systemic inflammation, has beenassociated with poor survival for many cancers. The aim of this study was to investigate the clinicalsignificance of blood NLR in nonsmall cell lung cancer (NSCLC) as a prognostic factor.METHODS: We retrospectively reviewed medical records of patients with NSCLC and collected datafrom December 2009 to September 2013. NLRs were calculated at the time of diagnosis before anytype of treatment. Data about NLR, age, sex, smoking, histopathology, Eastern Cooperative OncologyGroup (ECOG) performance score, disease stage, serum albumin, and treatment modalities wereinvestigated. These parameters were tested for its association with the 1‑year, 2‑year, and overallsurvival (OS); OS was calculated by the Kaplan–Meier analysis.RESULTS: A total of 121 patients with a median age of 61.9 (range 34–84), 14 (11.6%) female, and107 (88.4%) males were included in the study. Majority of the patients were at local or advancedstage (Stage IIIA: 14.9%, Stage IIIB 14.9%, and Stage IV: 48.8%). Most common histological tumortype was squamous cell carcinoma (56.2%). Median neutrophil (N) count was 6.400 μl/ml, medianlymphocyte (L) count was 1.570 μl/ml, while median NLR was 3.7. In univariate analysis, survival ratesof patients did not have any differences according to gender, age, tumor histology, albumin level, andtreatment modality (surgery and chemoradiotherapy). 1‑year and 2‑year survival rates of patients withECOG 0 were higher than ECOG 1, 2, 3 patients (P = 0.034). Survival rates of Stage 1 patients (P 3.7. The percentage of patients who survived at the 1‑year and 2‑yearwere higher in the NLR 3.7 groups (14 vs. 9 months, P = 0.036). The multivariate Cox regression analysisrevealed that the independent predictive factors for longer OS were low ECOG performance score (hazardratio [HR] 0.786, 95% confidence interval [CI]: 0.799–0.931, P = 0.001), early disease stage (HR 1.517,95% CI: 0.527–0.886, P < 0.001), and low NLR (HR 0.573, 95% CI: 0.440–0.962, P = 0 .036).

🔖

Cite This Article

YILDIRIM, F., ÖZTÜRK, C., SEVİMLİ, N., TÜRK, M., YURDAKUL, A. S., DEMİRCİ, N. Y. (2022). Does neutrophil-to-lymphocyte ratio have a role among the other prognostic factors of nonsmall cell lung cancer?. Eurasian Journal of Pulmonology, Cilt: 21 - Sayı: 3, 187–192. https://ajindex.com/articles/509660

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA CancerJ Clin 2017;67:7‑30
  2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ, et al. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225‑49
  3. Fan H, Shao ZY, Xiao YY, Xie ZH, Chen W, Xie H, et al. Incidence and survival of non‑small cell lung cancer in Shanghai: A population‑based cohort study. BMJ Open 2015;5:e009419
  4. Coleman MP, Forman D, Bryant H, Butler J, Rachet B, Maringe C, et al. Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995‑2007 (the international cancer benchmarking partnership): An analysis of population‑based cancer registry data. Lancet 2011;377:127‑38
  5. Tas F, Ciftci R, Kilic L, Karabulut S. Age is a prognostic factor affecting survival in lung cancer patients. Oncol Lett 2013;6:1507‑13
  6. Wainer Z, Wright GM, Gough K, Daniels MG, Choong P, Conron M, et al. Impact of sex on prognostic host factors in surgical patients with lung cancer. ANZ J Surg 2017;87:1015‑20
  7. Yoshino I, Maehara Y. Impact of smoking status on the biological behavior of lung cancer. Surg Today 2007;37:725‑34
  8. Woodard GA, Jones KD, Jablons DM. Lung cancer staging and prognosis. Cancer Treat Res 2016;170:47‑75
  9. Greenberg AK, Lee MS. Biomarkers for lung cancer: Clinical uses. Curr Opin Pulm Med 2007;13:249‑55
  10. Kobayashi T, Teruya M, Kishiki T, Kaneko S, Endo D, Takenaka Y, et al. Inflammation‑based prognostic score and number of lymph node metastases are independent prognostic factors in esophageal squamous cell carcinoma. Dig Surg 2010;27:232‑7
  11. Liu W, Ha M, Yin N. Combination of platelet count and lymphocyte to monocyte ratio is a prognostic factor in patients undergoing surgery for non‑small cell lung cancer. Oncotarget 2017;8:73198‑207
  12. Kacan T, Babacan NA, Seker M, Yucel B, Bahceci A, Eren AA, et al. Could the neutrophil to lymphocyte ratio be a poor prognostic factor for non small cell lung cancers? Asian Pac J Cancer Prev 2014;15:2089‑94
  13. Putila J, Guo NL. Combining COPD with clinical, pathological and demographic information refines prognosis and treatment response prediction of non‑small cell lung cancer. PLoS One 2014;9:e100994
  14. Travis WD, Brambilla E, Müller‑Hermelink HK, Harris CC. Pathology and Genetics: Tumours of the Lung, Pleura, Thymus and Heart. Lyon: IARC Press; 2004
  15. Balkwill F, Mantovani A. Inflammation and cancer: Back to Virchow? Lancet 2001;357:539‑45
  16. Galdiero MR, Garlanda C, Jaillon S, Marone G, Mantovani A. T